These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 37682172)

  • 1. ELOVL6 is associated with immunosuppression in lung adenocarcinoma through bioinformatics analysis.
    Chen B; Shen K; Zhang T; Gao WC
    Medicine (Baltimore); 2023 Sep; 102(36):e35013. PubMed ID: 37682172
    [TBL] [Abstract][Full Text] [Related]  

  • 2. EZH2 as a prognostic-related biomarker in lung adenocarcinoma correlating with cell cycle and immune infiltrates.
    Fan K; Zhang BH; Han D; Sun YC
    BMC Bioinformatics; 2023 Apr; 24(1):149. PubMed ID: 37069494
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In silico analysis reveals PRR11 as a prognostic and oncogenic marker in lung adenocarcinoma.
    Hu A; Tang K; Liu J; Han X; Chen Q
    Medicine (Baltimore); 2023 May; 102(21):e33755. PubMed ID: 37233443
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Mutational Signatures Analysis of Micropapillary Components and Exploration of ZNF469 Gene in Early-stage Lung Adenocarcinoma with Ground-glass Opacities].
    Xu Y; Sun Q; Wang S; Zhu H; Dong G; Meng F; Xia Z; You J; Kong X; Wu J; Chen P; Yuan F; Yu X; Ji J; Li Z; Zhu P; Sun Y; Liu T; Yin R; Xu L
    Zhongguo Fei Ai Za Zhi; 2024 Jan; 26(12):889-900. PubMed ID: 38151328
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Elevated ADAR expression is significantly linked to shorter overall survival and immune infiltration in patients with lung adenocarcinoma.
    Hu S; Wang F; Yang J; Xu X
    Math Biosci Eng; 2023 Sep; 20(10):18063-18082. PubMed ID: 38052548
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictions of the dysregulated competing endogenous RNA signature involved in the progression of human lung adenocarcinoma.
    Yang D; He Y; Wu B; Liu R; Wang N; Wang T; Luo Y; Li Y; Liu Y
    Cancer Biomark; 2020; 29(3):399-416. PubMed ID: 32741804
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High Expression of
    Chen Y; Zhou M; Gu X; Wang L; Wang C
    Dis Markers; 2022; 2022():8789515. PubMed ID: 35855850
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HMMR associates with immune infiltrates and acts as a prognostic biomaker in lung adenocarcinoma.
    Ma X; Xie M; Xue Z; Yao J; Wang Y; Xue X; Wang J
    Comput Biol Med; 2022 Dec; 151(Pt A):106213. PubMed ID: 36306573
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of
    Bian T; Zhang W; Wang F; Chu X; Pan X; Ruan J; Yu S; Liu L; Sun H; Qiu H; Li Y; Tang J; Zhao X; Zhang H
    Comb Chem High Throughput Screen; 2023; 26(14):2452-2468. PubMed ID: 37038295
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of the prognostic value in lung adenocarcinoma based on anoikis-related genes and initial experimental validation.
    Guo W; Zhao G; Liu S; Deng T; Zhang G; Zhang B
    J Gene Med; 2023 Sep; 25(9):e3534. PubMed ID: 37259225
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of a novel prognosis-associated ceRNA network in lung adenocarcinoma via bioinformatics analysis.
    Li Y; Yu X; Zhang Y; Wang X; Zhao L; Liu D; Zhao G; Gao X; Fu J; Zang A; Jia Y
    Biomed Eng Online; 2021 Nov; 20(1):117. PubMed ID: 34819106
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic value and immune infiltration of a novel stromal/immune score-related P2RY12 in lung adenocarcinoma microenvironment.
    Yu L; Cao S; Li J; Han B; Zhong H; Zhong R
    Int Immunopharmacol; 2021 Sep; 98():107734. PubMed ID: 34175738
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of UBE2C in lung adenocarcinoma based on database analysis and its clinical significance.
    Liu Y; Huang F; Chen H; Peng Q; Zhao C; Miao L
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2020 Sept 28; 45(9):1044-1052. PubMed ID: 33051417
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Correlation between prognostic indicator AHNAK2 and immune infiltrates in lung adenocarcinoma.
    Zheng M; Liu J; Bian T; Liu L; Sun H; Zhou H; Zhao C; Yang Z; Shi J; Liu Y
    Int Immunopharmacol; 2021 Jan; 90():107134. PubMed ID: 33168407
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vesicle-mediated transport-related genes are prognostic predictors and are associated with tumor immunity in lung adenocarcinoma.
    Qian C; Jiang Z; Zhou T; Wu T; Zhang Y; Huang J; Ouyang J; Dong Z; Wu G; Cao J
    Front Immunol; 2022; 13():1034992. PubMed ID: 36524130
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of PTGES3 on the Prognosis and Immune Regulation in Lung Adenocarcinoma.
    Jiang W; Wei Q; Xie H; Wu D; He H; Lv X
    Anal Cell Pathol (Amst); 2023; 2023():4522045. PubMed ID: 37416927
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of key genes and biological pathways in lung adenocarcinoma via bioinformatics analysis.
    Wang Y; Zhou Z; Chen L; Li Y; Zhou Z; Chu X
    Mol Cell Biochem; 2021 Feb; 476(2):931-939. PubMed ID: 33130972
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ECE2 is a prognostic biomarker associated with m6A modification and involved in immune infiltration of lung adenocarcinoma.
    Zhang YH; Zeng J; Liu XS; Gao Y; Kui XY; Liu XY; Zhang Y; Pei ZJ
    Front Endocrinol (Lausanne); 2022; 13():1013238. PubMed ID: 36299451
    [TBL] [Abstract][Full Text] [Related]  

  • 19. NPM1 Is a Prognostic Biomarker Involved in Immune Infiltration of Lung Adenocarcinoma and Associated With m6A Modification and Glycolysis.
    Liu XS; Zhou LM; Yuan LL; Gao Y; Kui XY; Liu XY; Pei ZJ
    Front Immunol; 2021; 12():724741. PubMed ID: 34335635
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comprehensive analysis of clinical prognosis and CLIC1 immune invasion in lung adenocarcinoma.
    Chen Z; Chen W; Huang R; Chen D; Li Z; Qi X; Sun L; Lin L; Zhang Z
    Medicine (Baltimore); 2022 Sep; 101(39):e30760. PubMed ID: 36181109
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.